LANGUAGE AND DURATION
Duration: 30 minutes, followed by questions from the audience
Presenter: Dr Hernan Amartino, Hospital Universitario Austral, Buenos Aires, Argentina
- Understanding why early diagnosis of MPS is vital for the early start of therapies and patient outcomes.
- Reviewing the latest options for treating patients with MPS based on presenting symptoms.
- Using Case Studies to understand better how the multidisciplinary team approach to managing MPS patients is so vital.
- Providing an overview of the current treatment options for each MPS disorder.
Misdiagnosis of Mucopolysaccharidosis (MPS) results in late diagnosis and the late start of treatment, which has significant consequences on long-term outcomes. This gap usually results in confusing symptoms with other conditions, most notably trying to address symptoms directly and delaying actual diagnosis and treatment or referring the patient to the wrong pediatric specialties, causing further delays in the condition’s management chain.
The Spot the Early Signs program aims to fight under-diagnosed or late-diagnosed conditions for which treatments are available and where early detection and treatment could make a significant difference in the condition's development, quality of life and survival of patients.
This educational activity is designed for an international audience of General Pediatricians, General Practitioners, Pediatric Endocrinologists, Pediatric Rheumatologists, and other physicians and healthcare professionals interested in Metabolic Diseases.